Your SlideShare is downloading. ×
Toxoplasmosis therapeutics   pipeline assessment and market forecasts to 2019
Toxoplasmosis therapeutics   pipeline assessment and market forecasts to 2019
Toxoplasmosis therapeutics   pipeline assessment and market forecasts to 2019
Toxoplasmosis therapeutics   pipeline assessment and market forecasts to 2019
Toxoplasmosis therapeutics   pipeline assessment and market forecasts to 2019
Toxoplasmosis therapeutics   pipeline assessment and market forecasts to 2019
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Toxoplasmosis therapeutics pipeline assessment and market forecasts to 2019

163

Published on

GlobalData, the industry analysis specialist, has released its new report, “Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of …

GlobalData, the industry analysis specialist, has released its new report, “Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
163
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019SummaryGlobalData, the industry analysis specialist, has released its new report, “ToxoplasmosisTherapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essentialsource of information and analysis on the global Toxoplasmosis Therapeutics market. The reportidentifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. Thereport also provides insights on the prevalent competitive landscape and the emerging playersexpected to significantly alter the market positioning of the current market leaders. Mostimportantly, the report provides valuable insights on the pipeline products within the globalToxoplasmosis Therapeutics sector. This report is built using data and information sourced fromproprietary databases, primary and secondary research and in-house analysis by GlobalData’s teamof industry experts.ScopeThe report provides information on the key drivers and challenges of the ToxoplasmosisTherapeutics market. Its scope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ToxoplasmosisTherapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.- Pipeline analysis data providing a split across the different phases, mechanisms of action beingdeveloped and emerging trends by seven key markets. Pipeline candidates fall under majortherapeutic classes.- Analysis of the current and future competition in the seven key countries ToxoplasmosisTherapeutics market.- Insightful review of the key industry drivers, restraints and challenges. Each trend isindependently researched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmetneeds and the implications for the Toxoplasmosis Therapeutics market.- Analysis of key recent licensing and partnership agreements in Toxoplasmosis TherapeuticsmarketReasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipelineproducts and technologies and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the globalToxoplasmosis Therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market
  • 2. segments and companies likely to impact the global Toxoplasmosis Therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscapeand by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments thatpresent maximum opportunities for consolidations, investments and strategic partnerships.- What’s the next big thing in the global Toxoplasmosis Therapeutics market landscape? – Identify,understand and capitalize.Buy Your Copy of Report: http://www.reportsnreports.com/reports/174214-toxoplasmosis-therapeutics-pipeline-assessment-and-market-forecasts-to-2019.htmlReport Details:Published: July 2012Price Single User License: US $ 3995 Price Corporate User License: US $ 11895Table of Contents1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 52 Toxoplasmosis Therapeutics - Introduction 62.1 Disease Overview 62.1.1 Types of Toxoplasma gondii Strain 72.1.2 Life Cycle and Transmission 72.2 Epidemiology 72.2.1 Historic Epidemiology (2006–2011) 82.2.2 Forecast Epidemiology (2011–2019) 92.3 Etiology 102.3.1 Food-borne Transmission 102.3.2 Congenital Transmission 102.3.3 Zoonotic Transmission 102.3.4 Rare Instances of Transmission 102.4 Pathophysiology 102.5 Signs and Symptoms 112.6 Commonly Used Diagnostic Tests 122.6.1 Types of Diagnostic Test 122.7 Treatment and Management Options for Toxoplasmosis 13
  • 3. 2.7.1 Management of Toxoplasmosis Infection during Gestation 142.7.2 Congenital Toxoplasmosis 142.7.3 Ocular Toxoplasmosis 152.7.4 Toxoplasmosis in Immunocompetent Patients 152.8 GlobalData Pipeline Report Guidance 163 Toxoplasmosis Therapeutics - Market Characterization 173.1 Toxoplasmosis Therapeutics Market Size (2006–2011) – Global 173.2 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Global 193.3 Toxoplasmosis Therapeutics Market Size (2006–2011) – The US 203.4 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – The US 213.5 Toxoplasmosis Therapeutics Market Size (2006–2011) – France 223.6 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – France 233.7 Toxoplasmosis Therapeutics Market Size (2006–2011) – Germany 243.8 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Germany 253.9 Toxoplasmosis Therapeutics Market Size (2006–2011) – Italy 263.10 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Italy 273.11 Toxoplasmosis Therapeutics Market Size (2006–2011) – Spain 283.12 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Spain 293.13 Toxoplasmosis Therapeutics Market Size (2006–2011) – The UK 303.14 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – The UK 313.15 Toxoplasmosis Therapeutics Market Size (2006–2011) – Japan 323.16 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Japan 333.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market 343.17.1 Drivers for the Toxoplasmosis Therapeutics Market 343.17.2 Barriers for the Toxoplasmosis Therapeutics Market 343.18 Opportunity and Unmet Need Analysis 353.19 Key Takeaway 364 Toxoplasmosis Therapeutics - Competitive Assessment 374.1 Overview 374.2 Strategic Competitor Assessment 374.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market 384.3.1 Daraprim (pyrimethamine) 384.3.2 Spiramycin 394.3.3 Sulfadiazine 394.3.4 Folinic Acid 404.4 Key Takeaway 405 Toxoplasmosis Therapeutics - Pipeline Assessment 415.1 Overview 415.2 Strategic Pipeline Assessment 415.2.1 Toxoplasmosis Therapeutics – Phase III Clinical Pipeline 415.3 Key Takeaway 416 Toxoplasmosis Therapeutics - Clinical Trial Mapping 42
  • 4. 6.1 Clinical Trials by Region and Country 426.2 Clinical Trials by Phase 436.3 Clinical Trials by Trial Status 446.4 Clinical Trial Mapping by Sponsors 456.5 Prominent Sponsors 466.6 Companies Participating in Toxoplasmosis Therapeutics Clinical Trials 467 Toxoplasmosis Therapeutics - Strategic Assessment 477.1 Key Events Impacting the Future Market 477.2 Toxoplasmosis Therapeutics: Implications for Future Market Competition 478 Toxoplasmosis Therapeutics Market - Licensing and Partnership Deals 489 Toxoplasmosis Therapeutics Market - KOL Insights, 2012 4910 Toxoplasmosis Therapeutics - Appendix 5010.1 Market Definitions 5010.2 Acronyms 5010.3 Bibliography 5010.4 Research Methodology 5210.4.1 Coverage 5210.4.2 Secondary Research 5210.4.3 Forecasting 5310.4.4 Primary Research 5510.4.5 Expert Panel Validation 5610.5 Contact Us 5610.6 Disclaimer 561.1 List of TablesTable 1: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2006-2011 8Table 2: Toxoplasmosis Therapeutics Market, Global, Prevalence, 2011-2019 9Table 3: Alternative Antibiotics Used in Ocular Toxoplasmosis 15Table 4: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18Table 5: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011-2019 19Table 6: Toxoplasmosis Therapeutics Market, The US, Revenue ($m), 2006-2011 20Table 7: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21Table 8: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006-2011 22Table 9: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011-2019 23Table 10: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 24Table 11: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 25Table 12: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 26Table 13: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 27Table 14: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 28Table 15: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 29Table 16: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 30Table 17: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 31
  • 5. Table 18: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32Table 19: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33Table 20: Toxoplasmosis Therapeutics-Phase III Pipeline, 2012 41Table 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42Table 22: Toxoplasmosis Therapeutics - Clinical Trials by Phase, 2012 43Table 23: Toxoplasmosis Therapeutics - Clinical Trials by Status, 2012 44Table 24: Toxoplasmosis Therapeutics - Overall Sponsors, 2012 45Table 25: Toxoplasmosis Therapeutics - Prominent Sponsors, 2012 46Table 26: Toxoplasmosis Therapeutics - Company Participating in Therapeutics Clinical Trials,2012 46Table 27: Toxoplasmosis-Global, Deals, 2012 48Table 28: Toxoplasmosis Therapeutics Market, Global, KOL Insights, 2012 491.2 List of FiguresFigure 1: Diagnosis Algorithm for Congenital Toxoplasmosis 12Figure 2: Approaches for the Treatment of Pregnant Women 14Figure 3: Toxoplasmosis Therapeutics Market, Global, Revenue ($m), 2006-2011 18Figure 4: Toxoplasmosis Therapeutics Market, Global, Forecast ($m), 2011–2019 19Figure 5: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2006–2011 20Figure 6: Toxoplasmosis Therapeutics Market, The US, Forecast ($m), 2011–2019 21Figure 7: Toxoplasmosis Therapeutics Market, France, Revenue ($m), 2006–2011 22Figure 8: Toxoplasmosis Therapeutics Market, France, Forecast ($m), 2011–2019 23Figure 9: Toxoplasmosis Therapeutics Market, Germany, Revenue ($m), 2006–2011 24Figure 10: Toxoplasmosis Therapeutics Market, Germany, Forecast ($m), 2011–2019 25Figure 11: Toxoplasmosis Therapeutics Market, Italy, Revenue ($m), 2006–2011 26Figure 12: Toxoplasmosis Therapeutics Market, Italy, Forecast ($m), 2011–2019 27Figure 13: Toxoplasmosis Therapeutics Market, Spain, Revenue ($m), 2006–2011 28Figure 14: Toxoplasmosis Therapeutics Market, Spain, Forecast ($m), 2011–2019 29Figure 15: Toxoplasmosis Therapeutics Market, The UK, Revenue ($m), 2006–2011 30Figure 16: Toxoplasmosis Therapeutics Market, The UK, Forecast ($m), 2011–2019 31Figure 17: Toxoplasmosis Therapeutics Market, Japan, Revenue ($m), 2006–2011 32Figure 18: Toxoplasmosis Therapeutics Market, Japan, Forecast ($m), 2011–2019 33Figure 19: Opportunity and Unmet Need in the Toxoplasmosis Therapeutics Market 36Figure 20: Toxoplasmosis Therapeutics - Strategic Competitor Assessment, 2012 38Figure 21: Toxoplasmosis Therapeutics - Clinical Trials by Country, 2012 42Figure 22: Toxoplasmosis Therapeutics – Clinical Trials by Phase, 2012 43Figure 23: Toxoplasmosis Therapeutics – Clinical Trials by Status, 2012 44Figure 24: Toxoplasmosis Therapeutics – Overall Sponsors, 2012 45Figure 25: Toxoplasmosis Therapeutics Market, Drivers and Barriers, 2012 47Figure 26: Implications for Future Market Competition in the Toxoplasmosis Therapeutics Market,2012 47
  • 6. Figure 27: GlobalData Market Size Estimation 53Figure 28: GlobalData Market Forecasting Model 55Browse more Research Reports @ http://www.reportsnreports.com/market-research/pharmaceuticals/Contact Us:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.+ 1 888 391 5441Email: sales@reportsandreports.comConnect With Us:

×